Granted Patent
B2
US 10,041,124 · App. 14/153,651 · Granted Aug 7, 2018
Methylation biomarkers for ovarian cancer
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Different combinations of methylation status based biomarkers can be used to test for ovarian cancer with high sensitivity and high specificity.
Claims (3)
1. A method comprising:
measuring, in a DNA sample from ovarian stroma, ovarian surface epithelial cells, or both, a methylation level in a CpG promoter island of each gene in a set of genes, wherein the set of genes consists of CYP39A1, DAPK1, CAV1, ARMCX1, ROCK1, MED1, SFRP1, and CCND2, and optionally any one or more of CDKN1B, MLH1, MED1, PEGS, BEX4, SPARC11, ARMCX2, PLAGL1, RAD51C, SOCS2, RARRES1, UCHL1 and DIRAS.
2. The method of claim 1 , wherein the methylation level is determined by methylation-specific PCR.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 15, 2016
From: MANSOUR, HICHAM; INCITTI, ROBERTO; BAJIC, VLADIMIR
To: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
Reel/Frame 040995/0883 →
Continuity (2)
Provisional Application
61752156
· Jan 14, 2013